Core Viewpoint - The Gross Law Firm is investigating potential securities fraud claims on behalf of investors of Ziff Davis, Inc. due to losses incurred from their investments [1]. Group 1 - The investigation is aimed at shareholders who have suffered losses related to Ziff Davis, Inc. investments [1]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights against deceit and fraud in business practices [2]. - The firm seeks recovery for investors affected by misleading statements or omissions that led to artificial inflation of the company's stock [2].

Core Viewpoint - Kaskela Law is investigating Agilon Health, Inc. on behalf of long-term investors due to allegations of securities fraud related to misleading statements about the company's medical costs [1][2]. Summary by Sections Investigation Details - A securities fraud complaint has been filed against Agilon for misleading investors about medical costs between April 15, 2021, and February 27, 2024 [2]. - The complaint alleges that Agilon and its senior executives made materially false statements, leading to a significant decline in stock value [3]. Financial Impact - Agilon's stock price fell approximately 85% during the relevant period, dropping from over $44.00 per share to less than $6.50 per share, a decline of over $38.00 per share [3]. Legal Concerns - The investigation focuses on whether Agilon's board of directors violated securities laws or breached fiduciary duties in connection with the alleged misconduct [4]. Shareholder Information - Current shareholders who acquired shares before May 1, 2023, are encouraged to contact Kaskela Law to discuss their legal rights and options regarding the investigation [5].

Core Viewpoint - Kaskela Law is investigating WEBTOON Entertainment Inc. for potential securities fraud related to disappointing financial results following its IPO, which may have led to significant losses for investors [1][3][4]. Group 1: Investigation Details - A securities fraud complaint was filed against WEBTOON on behalf of investors who purchased shares before August 9, 2024 [2]. - WEBTOON completed its IPO on June 28, 2024, selling 15 million shares at $21.00 per share, raising approximately $315 million [2]. - The company reported disappointing quarterly results on August 8, 2024, revealing "bleak revenue growth and substantial declines" in Monthly Active Users (MAUs) [3]. Group 2: Financial Impact - Following the disappointing quarterly report, WEBTOON's stock price fell by $7.88, or over 38%, closing at $12.75 per share on August 9, 2024, amid unusually heavy trading volume [3]. Group 3: Legal Implications - Kaskela Law is investigating whether WEBTOON's senior executives and directors violated securities laws or breached fiduciary duties, which may have contributed to investor losses [4][7]. - Long-term shareholders of WEBTOON may have unique legal rights and options that are not currently represented [7].

Core Viewpoint - Eos Energy is facing a class action lawsuit for securities fraud due to misrepresentations regarding its revenue growth and manufacturing capabilities, which led to a significant stock drop of approximately 39% [1][2][5]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Eos Energy Enterprises, Inc. and certain senior executives for securities fraud after the company's stock dropped around 39% [2][3]. - Investors have until May 5, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of New Jersey [3][6]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of Eos Energy investors [3]. Group 2: Company Performance and Allegations - Eos Energy manufactures zinc-based long-duration battery energy storage systems aimed at renewable power storage and grid reliability [3]. - The company had previously projected revenue guidance of $150 million to $160 million for fiscal year 2025, but these claims were allegedly misleading due to production inefficiencies and delays [4]. - On February 26, 2026, Eos reported a net loss of approximately $970 million for fiscal year 2025 and disclosed revenue that fell short of its guidance, leading to a stock price decline of $4.39 per share, or about 39.4% [5][6].

Core Viewpoint - ADMA Biologics is under investigation for potential securities fraud following a report by Culper Research, which alleged that the company's reported 20% revenue growth in 2025 was artificially inflated through a channel stuffing scheme, leading to a 29% drop in its stock price [1][3][4]. Company Overview - ADMA Biologics is a biopharmaceutical company focused on manufacturing and developing specialty biologics, with its flagship product being ASCENIV, a liquid immune globulin solution for treating Primary Humoral Immunodeficiency [2]. Investigation Details - Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential violations of federal securities laws, specifically regarding allegations of channel stuffing to misrepresent revenue figures [2][3]. - The investigation was prompted by a report from Culper Research, which claimed that ADMA Biologics induced a distributor to stock excess ASCENIV by offering rebates and extended payment terms, allowing the company to report growth that did not exist [3]. Stock Performance - Following the allegations, ADMA Biologics' stock price fell from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026, marking a decline of $3.96 per share or 29% [4].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and its executives for securities fraud, following a significant stock drop of 17% attributed to alleged misrepresentations regarding a $1.66 billion loan from the U.S. Department of Energy (DOE) [1][4]. Company Overview - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. Legal Proceedings - The lawsuit claims violations of federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with the case pending in the U.S. District Court for the Northern District of New York, titled Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3][8]. Stock Performance - Plug Power's stock experienced a notable decline following key events: - On October 7, 2025, the abrupt departure of CEO Andrew Marsh and President Sanjay Shrestha led to a 6.3% drop, from $4.13 to $3.87 per share [5]. - On November 10, 2025, the announcement of suspended activities under the DOE loan program caused a further decline of 3.4%, from $2.65 to $2.56 per share [6]. - The most significant drop occurred on November 14, 2025, when the stock fell 17.6%, from $2.49 to $2.25 per share, following reports of suspended plans for hydrogen production facilities [7]. Allegations - The lawsuit alleges that Plug Power materially overstated the likelihood of accessing DOE loan funds and constructing the necessary hydrogen production facilities, which misled investors [4][8].

Core Viewpoint - Rosen Law Firm is reminding investors of BlackRock TCP Capital Corp. about the opportunity to lead a securities fraud lawsuit due to significant losses incurred during the specified class period [1]. Group 1: Lawsuit Details - The class period for the lawsuit is defined as November 6, 2024, to January 23, 2026, with a lead plaintiff deadline set for April 6, 2026 [1]. - Investors who purchased BlackRock TCP securities during this period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about BlackRock TCP's business and operations, leading to understated unrealized losses and overstated net asset value (NAV) [5]. Group 2: Actions for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by the April 6, 2026 deadline [3]. - Until a class is certified, investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [7]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Richtech Robotics Inc. is facing a securities fraud lawsuit due to misleading statements regarding its relationship with Microsoft, which has led to investor losses during the specified class period [5]. Group 1: Lawsuit Details - The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Richtech securities between January 27, 2026, and January 29, 2026, with a lead plaintiff deadline set for April 3, 2026 [1][3]. - The lawsuit alleges that Richtech falsely claimed a collaborative relationship with Microsoft, which misled investors about the company's business and prospects [5]. Group 2: Investor Participation - Investors who suffered losses exceeding $100,000 during the class period may be eligible for compensation without upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the Rosen Law Firm's website or contact them directly [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities litigation, being ranked highly for the number of settlements achieved [4].

Core Viewpoint - ImmunityBio, Inc. is facing a securities fraud class action lawsuit due to a significant stock decline of 21% following an FDA warning regarding misleading advertising related to its cancer treatment, Anktiva [1][4]. Company Overview - ImmunityBio, Inc. (NasdaqGS: IBRX) is under scrutiny for failing to disclose material information during the class period from January 19, 2026, to March 24, 2026 [3][5]. - The company's stock price fell by $1.98, closing at $7.42 per share on March 24, 2026, after the FDA's warning letter was made public [4]. Legal Proceedings - Investors who suffered substantial losses have until May 26, 2026, to file lead plaintiff applications in the ongoing class action lawsuit against ImmunityBio [1][5]. - The lawsuit is currently pending in the United States District Court for the Central District of California, under the case name Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261 [5]. FDA Warning Details - The FDA issued a warning letter on March 13, 2026, indicating that ImmunityBio's promotional materials misrepresented Anktiva, suggesting it could cure and prevent all cancers, which violates the Federal Food, Drug, and Cosmetic Act [4].

Core Viewpoint - PomDoctor Ltd. is facing a securities fraud lawsuit, with a lead plaintiff deadline set for April 7, 2026, for investors who incurred losses exceeding $100,000 during the class period from October 9, 2025, to December 11, 2025 [1]. Group 1: Lawsuit Details - The lawsuit alleges that PomDoctor made false and misleading statements and failed to disclose critical information regarding a fraudulent stock promotion scheme, insider trading, and misleading public statements about its business and operations [5]. - Investors who purchased PomDoctor securities during the class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - A class action lawsuit has already been filed, and interested investors can join by submitting a form or contacting the firm directly [3][6].